Effect of a Nutritional Supplement on Posaconazole Pharmacokinetics following Oral Administration to Healthy Volunteers

ABSTRACT We conducted a randomized, crossover study in healthy adults to examine the effects of a nutritional supplement (Boost Plus) on posaconazole pharmacokinetics. In this study, coadministration of posaconazole with Boost Plus increased the maximum concentration of posaconazole in serum and area under the concentration-time curve from 0 to 72 h values 3.4- and 2.6-fold, respectively, compared to those for the fasted state.

[1]  J. Graybill,et al.  Refractory coccidioidomycosis treated with posaconazole. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  S. Swan,et al.  Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease , 2005, Journal of clinical pharmacology.

[3]  R. Courtney,et al.  Disposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects , 2004, Antimicrobial Agents and Chemotherapy.

[4]  C. Banfield,et al.  Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[5]  E. Radwanski,et al.  Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men , 2004, Antimicrobial Agents and Chemotherapy.

[6]  E. Radwanski,et al.  Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. , 2003, British journal of clinical pharmacology.

[7]  M. Pfaller,et al.  Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi , 2003, Journal of Clinical Microbiology.

[8]  J. Meis,et al.  In vitro susceptibilities of zygomycetes to conventional and new antifungals. , 2003, The Journal of antimicrobial chemotherapy.

[9]  J. Graybill,et al.  In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes , 2002, Antimicrobial Agents and Chemotherapy.

[10]  M. Pfaller,et al.  Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000 , 2002, Antimicrobial Agents and Chemotherapy.

[11]  A. Espinel-Ingroff.  Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts , 1998, Journal of Clinical Microbiology.